nach oben

Erschienen in:

05.06.2021 | Special Section: Ovarian Cancer

Current update on malignant epithelial ovarian tumors

verfasst von: Sherif B. Elsherif, Priya R. Bhosale, Chandana Lall, Christine O. Menias, Malak Itani, Kristina A. Butler, Dhakshinamoorthy Ganeshan

Erschienen in: Abdominal Radiology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Epithelial ovarian cancer (EOC) represents the most frequently occurring gynecological malignancy, accounting for more than 70% of ovarian cancer deaths. Preoperative imaging plays an important role in assessing the extent of disease and guides the next step in surgical decision-making and operative planning. In this article, we will review the multimodality imaging features of various subtypes of EOC. We will also discuss the role of imaging in the staging, management, and surveillance of EOC.

Liu D, Zhang L, Indima N, Peng K, Li Q, Hua T, Tang G (2017) CT and MRI findings of type I and type II epithelial ovarian cancer. European Journal of Radiology 90:225–233. https://doi.org/10.1016/j.ejrad.2017.02.017CrossRefPubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68 (6):394–424CrossRefPubMed

Signorelli M, Guerra L, Pirovano C, Crivellaro C, Fruscio R, Buda A, Cuzzucrea M, Elisei F, Ceppi L, Messa C (2013) Detection of nodal metastases by 18F-FDG PET/CT in apparent early stage ovarian cancer: a prospective study. Gynecol Oncol 131 (2):395–399. https://doi.org/10.1016/j.ygyno.2013.08.022CrossRefPubMed

Eoh KJ, Park HS, Park JS, Lee ST, Han J, Lee JY, Kim SW, Kim S, Kim YT, Nam EJ (2017) Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients. Cancer Res Treat 49 (2):408–415. https://doi.org/10.4143/crt.2016.135CrossRefPubMed

Kang SK, Reinhold C, Atri M, Benson CB, Bhosale PR, Jhingran A, Lakhman Y, Maturen KE, Nicola R, Pandharipande PV, Salazar GM, Shipp TD, Simpson L, Small W, Jr., Sussman BL, Uyeda JW, Wall DJ, Whitcomb BP, Zelop CM, Glanc P (2018) ACR Appropriateness Criteria(®) Staging and Follow-Up of Ovarian Cancer. Journal of the American College of Radiology: JACR 15 (5s):S198–S207. https://doi.org/10.1016/j.jacr.2018.03.015CrossRefPubMed

Orr B, Edwards RP (2018) Diagnosis and Treatment of Ovarian Cancer. Hematol Oncol Clin North Am 32 (6):943–964. https://doi.org/10.1016/j.hoc.2018.07.010CrossRefPubMed

Wang F, Wang Y, Zhou Y, Liu C, Xie L, Zhou Z, Liang D, Shen Y, Yao Z, Liu J (2017) Comparison between types I and II epithelial ovarian cancer using histogram analysis of monoexponential, biexponential, and stretched-exponential diffusion models. J Magn Reson Imaging 46 (6):1797–1809. https://doi.org/10.1002/jmri.25722CrossRefPubMed

Au KK, Josahkian JA, Francis JA, Squire JA, Koti M (2015) Current state of biomarkers in ovarian cancer prognosis. Future Oncol 11 (23):3187–3195. https://doi.org/10.2217/fon.15.251CrossRefPubMed

Elsherif S, Javadi S, Viswanathan C, Faria S, Bhosale P (2019) Low-grade epithelial ovarian cancer: what a radiologist should know. Br J Radiol 92 (1095):20180571. https://doi.org/10.1259/bjr.20180571CrossRefPubMedPubMedCentral

10.

Elsherif SB, Faria SC, Lall C, Iyer R, Bhosale PR (2019) Ovarian Cancer Genetics and Implications for Imaging and Therapy. J Comput Assist Tomogr 43 (6):835–845. https://doi.org/10.1097/rct.0000000000000932CrossRefPubMed

11.

Integrated genomic analyses of ovarian carcinoma: the Cancer Genome Atlas Research Network (2011). Nature 474 (7353):609. https://doi.org/10.1038/nature10166

12.

Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, Cecere SC, Gargiulo P, Pignata S (2015) Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. Cancer Treat Rev 41 (2):136–143. https://doi.org/10.1016/j.ctrv.2014.12.003CrossRefPubMed

13.

Mangili G, Bergamini A, Taccagni G, Gentile C, Panina P, Vigano P, Candiani M (2012) Unraveling the two entities of endometrioid ovarian cancer: a single center clinical experience. Gynecol Oncol 126 (3):403–407. https://doi.org/10.1016/j.ygyno.2012.05.007CrossRefPubMed

14.

Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA, Jr., Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330 (6001):228–231. https://doi.org/10.1126/science.1196333CrossRefPubMedPubMedCentral

15.

Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM (2010) Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol 117 (3):491–496. https://doi.org/10.1016/j.ygyno.2010.02.010CrossRefPubMedPubMedCentral

16.

Marko J, Marko KI, Pachigolla SL, Crothers BA, Mattu R, Wolfman DJ (2019) Mucinous Neoplasms of the Ovary: Radiologic–Pathologic Correlation. Radiographics 39 (4):982–997. https://doi.org/10.1148/rg.2019180221CrossRefPubMed

17.

Rojas V, Hirshfield KM, Ganesan S, Rodriguez-Rodriguez L (2016) Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. Int J Mol Sci 17 (12):2113. https://doi.org/10.3390/ijms17122113CrossRefPubMedCentral

18.

Romero I, Sun CC, Wong KK, Bast RC, Jr., Gershenson DM (2013) Low-grade serous carcinoma: new concepts and emerging therapies. Gynecol Oncol 130 (3):660–666. https://doi.org/10.1016/j.ygyno.2013.05.021CrossRefPubMed

19.

Martins FC, Santiago I, Trinh A, Xian J, Guo A, Sayal K, Jimenez-Linan M, Deen S, Driver K, Mack M, Aslop J, Pharoah PD, Markowetz F, Brenton JD (2014) Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol 15 (12):526. https://doi.org/10.1186/s13059-014-0526-8CrossRefPubMedPubMedCentral

20.

Eoh KJ, Kim HM, Lee JY, Kim S, Kim SW, Kim YT, Nam EJ (2020) Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. BMC Cancer 20 (1):204. https://doi.org/10.1186/s12885-020-6693-yCrossRefPubMedPubMedCentral

21.

Javadi S, Ganeshan DM, Qayyum A, Iyer RB, Bhosale P (2016) Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging. Am J Roentgenol 206 (6):1351–1360. https://doi.org/10.2214/AJR.15.15199CrossRef

22.

Previs RA, Sood AK, Mills GB, Westin SN (2016) The rise of genomic profiling in ovarian cancer. Expert Rev Mol Diagn 16 (12):1337–1351. https://doi.org/10.1080/14737159.2016.1259069CrossRefPubMedPubMedCentral

23.

Zhang W, Wang L, Xin Z (2018) Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer. Medicine (Baltimore) 97 (16):e0358. https://doi.org/10.1097/md.0000000000010358CrossRef

24.

Nougaret S, Lakhman Y, Molinari N, Feier D, Scelzo C, Vargas HA, Sosa RE, Hricak H, Soslow RA, Grisham RN, Sala E (2018) CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas. Am J Roentgenol 210 (4):918–926. https://doi.org/10.2214/AJR.17.18254CrossRef

25.

Ganeshan D, Bhosale P, Wei W, Ramalingam P, Mudasiru-Dawodu E, Gershenson D, Sun C, Iyer R (2016) Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer. Abdom Radiol (NY) 41 (8):1589–1595. https://doi.org/10.1007/s00261-016-0701-3CrossRef

26.

Tanaka YO, Okada S, Satoh T, Matsumoto K, Oki A, Saida T, Yoshikawa H, Minami M (2016) Differentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: a detailed analysis. Cancer Imaging 16:3. https://doi.org/10.1186/s40644-016-0061-9CrossRefPubMedPubMedCentral

27.

Vargas HA, Huang EP, Lakhman Y, Ippolito JE, Bhosale P, Mellnick V, Shinagare AB, Anello M, Kirby J, Fevrier-Sullivan B, Freymann J, Jaffe CC, Sala E (2017) Radiogenomics of High-Grade Serous Ovarian Cancer: Multireader Multi-Institutional Study from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group. Radiology 285 (2):482–492. https://doi.org/10.1148/radiol.2017161870CrossRefPubMed

28.

Nougaret S, Lakhman Y, Gonen M, Goldman DA, Micco M, D'Anastasi M, Johnson SA, Juluru K, Arnold AG, Sosa RE, Soslow RA, Vargas HA, Hricak H, Kauff ND, Sala E (2017) High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes. Radiology 285 (2):472–481. https://doi.org/10.1148/radiol.2017161697CrossRefPubMed

29.

Lindgren A, Anttila M, Arponen O, Rautiainen S, Könönen M, Vanninen R, Sallinen H (2019) Prognostic value of preoperative dynamic contrast-enhanced magnetic resonance imaging in epithelial ovarian cancer. Eur J Radiol 115:66–73. https://doi.org/10.1016/j.ejrad.2019.03.023CrossRefPubMed

30.

Moro F, Magoga G, Pasciuto T, Mascilini F, Moruzzi MC, Fischerova D, Savelli L, Giunchi S, Mancari R, Franchi D, Czekierdowski A, Froyman W, Verri D, Epstein E, Chiappa V, Guerriero S, Zannoni GF, Timmerman D, Scambia G, Valentin L, Testa AC (2018) Imaging in gynecological disease (13): clinical and ultrasound characteristics of endometrioid ovarian cancer. Ultrasound Obstet Gynecol 52 (4):535–543. https://doi.org/10.1002/uog.19026CrossRefPubMed

31.

Stein EB, Wasnik AP, Sciallis AP, Kamaya A, Maturen KE (2017) MR Imaging-Pathologic Correlation in Ovarian Cancer. Magn Reson Imaging Clin N Am 25 (3):545–562. https://doi.org/10.1016/j.mric.2017.03.004CrossRefPubMed

32.

Pozzati F, Moro F, Pasciuto T, Gallo C, Ciccarone F, Franchi D, Mancari R, Giunchi S, Timmerman D, Landolfo C, Epstein E, Chiappa V, Fischerova D, Fruscio R, Zannoni GF, Valentin L, Scambia G, Testa AC (2018) Imaging in gynecological disease (14): clinical and ultrasound characteristics of ovarian clear cell carcinoma. Ultrasound Obstet Gynecol 52 (6):792–800. https://doi.org/10.1002/uog.19171CrossRefPubMed

33.

Thomsen LH, Schnack TH, Buchardi K, Hummelshoj L, Missmer SA, Forman A, Blaakaer J (2017) Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review. Acta Obstet Gynecol Scand 96 (6):761–778. https://doi.org/10.1111/aogs.13010CrossRefPubMed

34.

Castellani F, Nganga EC, Dumas L, Banerjee S, Rockall AG (2019) Imaging in the pre-operative staging of ovarian cancer. Abdom Radiol (NY) 44 (2):685–696. https://doi.org/10.1007/s00261-018-1779-6CrossRef

35.

Tanase Y, Kawaguchi R, Takahama J, Kobayashi H (2018) Factors that Differentiate between Endometriosis-associated Ovarian Cancer and Benign Ovarian Endometriosis with Mural Nodules. Magn Reson Med Sci 17 (3):231–237. https://doi.org/10.2463/mrms.mp.2016-0149CrossRefPubMed

36.

Liu T, Sumida D, Wada T, Maehana T, Yamawaki A, Sugimoto S, Kawahara N, Yoshimoto C, Kobayashi H (2019) A diagnostic challenge of seromucinous borderline tumor: A case report. Medicine (Baltimore) 98 (22):e15707. https://doi.org/10.1097/md.0000000000015707CrossRef

37.

Kato H, Hatano Y, Makino H, Furui T, Morishige KI, Matsuo M (2016) Clear cell carcinoma of the ovary: comparison of MR findings of histological subtypes. Abdom Radiol (NY) 41 (12):2476–2483. https://doi.org/10.1007/s00261-016-0777-9CrossRef

38.

Ma FH, Qiang JW, Zhang GF, Li HM, Cai SQ, Rao YM (2016) Magnetic resonance imaging for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma. J Ovarian Res 9 (1):40. https://doi.org/10.1186/s13048-016-0251-xCrossRefPubMedPubMedCentral

39.

Morioka S, Kawaguchi R, Yamada Y, Iwai K, Yoshimoto C, Kobayashi H (2019) Magnetic resonance imaging findings for discriminating clear cell carcinoma and endometrioid carcinoma of the ovary. J Ovarian Res 12 (1):20. https://doi.org/10.1186/s13048-019-0497-1CrossRefPubMedPubMedCentral

40.

Moro F, Zannoni GF, Arciuolo D, Pasciuto T, Amoroso S, Mascilini F, Mainenti S, Scambia G, Testa AC (2017) Imaging in gynecological disease (11): clinical and ultrasound features of mucinous ovarian tumors. Ultrasound Obstet Gynecol 50 (2):261–270. https://doi.org/10.1002/uog.17222CrossRefPubMed

41.

Shetty M (2019) Imaging and Differential Diagnosis of Ovarian Cancer. Semin Ultrasound CT MR 40 (4):302–318. https://doi.org/10.1053/j.sult.2019.04.002CrossRefPubMed

42.

Seidman JD, Kurman RJ, Ronnett BM (2003) Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 27 (7):985–993. https://doi.org/10.1097/00000478-200307000-00014CrossRefPubMed

43.

Weinberger V, Minář L, Felsinger M, Ovesná P, Bednaříková M, Číhalová M, Jandáková E, Hausnerová J, Chaloupková B, Zikán M (2018) Brenner tumor of the ovary - ultrasound features and clinical management of a rare ovarian tumor mimicking ovarian cancer. Ginekol Pol 89 (7):357–363. https://doi.org/10.5603/GP.a2018.0061CrossRefPubMed

44.

Atri M, Alabousi A, Reinhold C, Akin EA, Benson CB, Bhosale PR, Kang SK, Lakhman Y, Nicola R, Pandharipande PV, Patel MD, Salazar GM, Shipp TD, Simpson L, Sussman BL, Uyeda JW, Wall DJ, Whitcomb BP, Zelop CM, Glanc P (2019) ACR Appropriateness Criteria(®) Clinically Suspected Adnexal Mass, No Acute Symptoms. Journal of the American College of Radiology 16 (5s):S77–S93. https://doi.org/10.1016/j.jacr.2019.02.011CrossRefPubMed

45.

Zacharakis D, Thomakos N, Biliatis I, Rodolakis A, Simou M, Daskalakis G, Bamias A, Antsaklis A (2013) Ultrasonographic markers and preoperative CA-125 to distinguish between borderline ovarian tumors and stage I ovarian cancer. Acta Obstet Gynecol Scand 92 (3):285–292. https://doi.org/10.1111/aogs.12046CrossRefPubMed

46.

Froyman W, Timmerman D (2019) Methods of Assessing Ovarian Masses: International Ovarian Tumor Analysis Approach. Obstet Gynecol Clin North Am 46 (4):625–641. https://doi.org/10.1016/j.ogc.2019.07.003CrossRefPubMed

47.

Abramowicz JS, Timmerman D (2017) Ovarian mass-differentiating benign from malignant: the value of the International Ovarian Tumor Analysis ultrasound rules. Am J Obstet Gynecol 217 (6):652–660. https://doi.org/10.1016/j.ajog.2017.07.019CrossRefPubMed

48.

Kaijser J, Sayasneh A, Van Hoorde K, Ghaem-Maghami S, Bourne T, Timmerman D, Van Calster B (2014) Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis. Hum Reprod Update 20 (3):449–462. https://doi.org/10.1093/humupd/dmt059CrossRefPubMed

49.

Andreotti RF, Timmerman D, Strachowski LM, Froyman W, Benacerraf BR, Bennett GL, Bourne T, Brown DL, Coleman BG, Frates MC, Goldstein SR, Hamper UM, Horrow MM, Hernanz-Schulman M, Reinhold C, Rose SL, Whitcomb BP, Wolfman WL, Glanc P (2020) O-RADS US Risk Stratification and Management System: A Consensus Guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee. Radiology 294 (1):168–185. https://doi.org/10.1148/radiol.2019191150CrossRefPubMed

50.

Basha MAA, Metwally MI, Gamil SA, Khater HM, Aly SA, El Sammak AA, Zaitoun MMA, Khattab EM, Azmy TM, Alayouty NA, Mohey N, Almassry HN, Yousef HY, Ibrahim SA, Mohamed EA, Mohamed AEM, Afifi AHM, Harb OA, Algazzar HY (2020) Comparison of O-RADS, GI-RADS, and IOTA simple rules regarding malignancy rate, validity, and reliability for diagnosis of adnexal masses. Eur Radiol. https://doi.org/10.1007/s00330-020-07143-7CrossRefPubMed

51.

Pereira PN, Sarian LO, Yoshida A, Araújo KG, Barros RH, Baião AC, Parente DB, Derchain S (2018) Accuracy of the ADNEX MR scoring system based on a simplified MRI protocol for the assessment of adnexal masses. Diagn Interv Radiol 24 (2):63PubMedPubMedCentral

52.

Ruiz M, Labauge P, Louboutin A, Limot O, Fauconnier A, Huchon C (2016) External validation of the MR imaging scoring system for the management of adnexal masses. Eur J Obstet Gynecol Reprod Biol 205:115–119. https://doi.org/10.1016/j.ejogrb.2016.07.493CrossRefPubMed

53.

Lu J, Pi S, Ma FH, Zhao SH, Li HM, Cai SL, Qiang JW (2019) Value of normalized apparent diffusion coefficients in differentiating between borderline and malignant epithelial ovarian tumors. Eur J Radiol 118:44–50. https://doi.org/10.1016/j.ejrad.2019.06.020CrossRefPubMed

54.

Zhang G, Yao W, Sun T, Liu X, Zhang P, Jin J, Bai Y, Hua K, Zhang H (2019) Magnetic resonance imaging in categorization of ovarian epithelial cancer and survival analysis with focus on apparent diffusion coefficient value: correlation with Ki-67 expression and serum cancer antigen-125 level. J Ovarian Res 12 (1):59. https://doi.org/10.1186/s13048-019-0534-0CrossRefPubMedPubMedCentral

55.

Moro F, Pasciuto T, Djokovic D, Di Legge A, Granato V, Moruzzi MC, Mancari R, Zannoni GF, Fischerova D, Franchi D, Scambia G, Testa AC (2019) Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses. Ultrasound Obstet Gynecol 53 (1):116–123. https://doi.org/10.1002/uog.19174CrossRefPubMed

56.

Xu Y, Yang J, Zhang Z, Zhang G (2015) MRI for discriminating metastatic ovarian tumors from primary epithelial ovarian cancers. J Ovarian Res 8:61. https://doi.org/10.1186/s13048-015-0188-5CrossRefPubMedPubMedCentral

57.

Elsherif SB, Zheng S, Ganeshan D, Iyer R, Wei W, Bhosale PR (2020) Does dual-energy CT differentiate benign and malignant ovarian tumours? Clin Radiol 75 (8):606–614. https://doi.org/10.1016/j.crad.2020.03.006CrossRefPubMed

58.

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic O, Long Roche KC, Sonoda Y, Coleman RL, Abu-Rustum NR, Hricak H, Chi DS (2017) A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecol Oncol 145 (1):27–31. https://doi.org/10.1016/j.ygyno.2017.02.020CrossRefPubMedPubMedCentral

59.

Rizzo S, Del Grande M, Manganaro L, Papadia A, Del Grande F (2020) Imaging before cytoreductive surgery in advanced ovarian cancer patients. Int J Gynecol Cancer 30 (1):133–138. https://doi.org/10.1136/ijgc-2019-000819CrossRefPubMed

60.

Hynninen J, Laasik M, Vallius T, Kemppainen J, Grönroos S, Virtanen J, Casado J, Hautaniemi S, Grenman S, Seppänen M, Auranen A (2018) Clinical Value of (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Response Evaluation after Primary Treatment of Advanced Epithelial Ovarian Cancer. Clin Oncol (R Coll Radiol) 30 (8):507–514. https://doi.org/10.1016/j.clon.2018.04.007CrossRef

61.

Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T (2016) Precision targeted therapy of ovarian cancer. J Control Release 243:250–268. https://doi.org/10.1016/j.jconrel.2016.10.014CrossRefPubMedPubMedCentral

62.

Nasser S, Lazaridis A, Evangelou M, Jones B, Nixon K, Kyrgiou M, Gabra H, Rockall A, Fotopoulou C (2016) Correlation of pre-operative CT findings with surgical & histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: A retrospective evaluation. Gynecol Oncol 143 (2):264–269. https://doi.org/10.1016/j.ygyno.2016.08.322CrossRefPubMed

63.

Fuso L, Ferrero A, Vietti E, Petracchini M, Mineccia M, Villa M, Menato G (2019) Development of a preoperative computed tomography score for the management of advanced epithelial ovarian cancer. Int J Gynecol Cancer 29 (3):599–604. https://doi.org/10.1136/ijgc-2018-000054CrossRefPubMed

64.

Sahdev A (2016) CT in ovarian cancer staging: how to review and report with emphasis on abdominal and pelvic disease for surgical planning. Cancer Imaging 16 (1):19. https://doi.org/10.1186/s40644-016-0076-2CrossRefPubMedPubMedCentral

65.

Rutten MJ, van de Vrie R, Bruining A, Spijkerboer AM, Mol BW, Kenter GG, Buist MR (2015) Predicting surgical outcome in patients with International Federation of Gynecology and Obstetrics stage III or IV ovarian cancer using computed tomography: a systematic review of prediction models. Int J Gynecol Cancer 25 (3):407–415. https://doi.org/10.1097/igc.0000000000000368CrossRefPubMed

66.

Qin L, Huang H, Chen M, Liang Y, Wang H (2018) Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer. J Ovarian Res 11 (1):49. https://doi.org/10.1186/s13048-018-0422-zCrossRefPubMedPubMedCentral

67.

Lindgren A, Anttila M, Rautiainen S, Arponen O, Kivelä A, Mäkinen P, Härmä K, Hämäläinen K, Kosma VM, Ylä-Herttuala S, Vanninen R, Sallinen H (2017) Primary and metastatic ovarian cancer: Characterization by 3.0 T diffusion-weighted MRI. Eur Radiol 27 (9):4002–4012. https://doi.org/10.1007/s00330-017-4786-zCrossRef

68.

Lindgren A, Anttila M, Rautiainen S, Arponen O, Hämäläinen K, Könönen M, Vanninen R, Sallinen H (2019) Dynamic contrast-enhanced perfusion parameters in ovarian cancer: Good accuracy in identifying high HIF-1α expression. PLoS ONE 14 (8):e0221340. https://doi.org/10.1371/journal.pone.0221340CrossRefPubMedPubMedCentral

69.

Hynninen J, Kemppainen J, Lavonius M, Virtanen J, Matomäki J, Oksa S, Carpén O, Grénman S, Seppänen M, Auranen A (2013) A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer. Gynecol Oncol 131 (2):389–394. https://doi.org/10.1016/j.ygyno.2013.08.023CrossRefPubMed

70.

Lopez-Lopez V, Cascales-Campos PA, Gil J, Frutos L, Andrade RJ, Fuster-Quiñonero M, Feliciangeli E, Gil E, Parrilla P (2016) Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue. Eur J Radiol 85 (10):1824–1828. https://doi.org/10.1016/j.ejrad.2016.08.006CrossRefPubMed

71.

Liu S, Feng Z, Wen H, Jiang Z, Pan H, Deng Y, Zhang L, Ju X, Chen X, Wu X (2018) F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value. Japanese journal of radiology 36 (9):544–550. https://doi.org/10.1007/s11604-018-0755-yCrossRefPubMed

72.

Vallius T, Hynninen J, Kemppainen J, Alves V, Auranen K, Matomäki J, Oksa S, Virtanen J, Grénman S, Auranen A, Seppänen M (2018) (18)F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer. Eur J Nucl Med Mol Imaging 45 (7):1224–1232. https://doi.org/10.1007/s00259-018-3961-zCrossRefPubMed

73.

Chung HH, Lee M, Kim HS, Kim JW, Park NH, Song YS, Cheon GJ (2017) Prognostic implication of the metastatic lesion-to-ovarian cancer standardised uptake value ratio in advanced serous epithelial ovarian cancer. Eur Radiol 27 (11):4510–4515. https://doi.org/10.1007/s00330-017-4883-zCrossRefPubMed

74.

Paik ES, Kim TJ, Lee YY, Choi CH, Lee JW, Kim BG, Bae DS (2016) Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer. J Gynecol Oncol 27 (5):e46. https://doi.org/10.3802/jgo.2016.27.e46CrossRefPubMedPubMedCentral

75.

Manganaro L, Gigli S, Antonelli A, Saldari M, Tomao F, Marchetti C, Anastasi E, Laghi A (2019) Imaging strategy in recurrent ovarian cancer: a practical review. Abdom Radiol (NY) 44 (3):1091–1102. https://doi.org/10.1007/s00261-018-1677-yCrossRef

76.

Guo N, Peng Z (2017) Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study. J Ovarian Res 10 (1):14. https://doi.org/10.1186/s13048-017-0310-yCrossRefPubMedPubMedCentral

77.

Yang WL, Lu Z, Bast RC, Jr. (2017) The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn 17 (6):577–591. https://doi.org/10.1080/14737159.2017.1326820CrossRefPubMedPubMedCentral

78.

Hameeduddin A, Sahdev A (2015) Diffusion-weighted imaging and dynamic contrast-enhanced MRI in assessing response and recurrent disease in gynaecological malignancies. Cancer Imaging 15 (1):3. https://doi.org/10.1186/s40644-015-0037-1CrossRefPubMedPubMedCentral

79.

Gu P, Pan LL, Wu SQ, Sun L, Huang G (2009) CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. European Journal of Radiology 71 (1):164–174. https://doi.org/10.1016/j.ejrad.2008.02.019CrossRefPubMed

80.

Lee YJ, Kim YM, Jung PS, Lee JJ, Kim JK, Kim YT, Nam JH (2018) Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients. J Gynecol Oncol 29 (3):e36. https://doi.org/10.3802/jgo.2018.29.e36CrossRefPubMedPubMedCentral

81.

Kim CY, Jeong SY, Chong GO, Son SH, Jung JH, Kim DH, Lee SW, Ahn BC, Lee J (2015) Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. Gynecol Oncol 136 (3):498–504. https://doi.org/10.1016/j.ygyno.2014.12.032CrossRefPubMed

82.

Grueneisen J, Schaarschmidt BM, Heubner M, Suntharalingam S, Milk I, Kinner S, Heubner A, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L (2015) Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies: A comparison to PET/CT. European Journal of Radiology 84 (11):2097–2102. https://doi.org/10.1016/j.ejrad.2015.08.010CrossRefPubMed

83.

Wang S, Liu Z, Rong Y, Zhou B, Bai Y, Wei W, Wei W, Wang M, Guo Y, Tian J (2019) Deep learning provides a new computed tomography-based prognostic biomarker for recurrence prediction in high-grade serous ovarian cancer. Radiother Oncol 132:171–177. https://doi.org/10.1016/j.radonc.2018.10.019CrossRefPubMed

84.

Qiu Y, Tan M, McMeekin S, Thai T, Ding K, Moore K, Liu H, Zheng B (2016) Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. Acta Radiol 57 (9):1149–1155. https://doi.org/10.1177/0284185115620947CrossRefPubMed

85.

Zhang H, Mao Y, Chen X, Wu G, Liu X, Zhang P, Bai Y, Lu P, Yao W, Wang Y, Yu J, Zhang G (2019) Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: a preliminary study. Eur Radiol 29 (7):3358–3371. https://doi.org/10.1007/s00330-019-06124-9CrossRefPubMed

Titel: Current update on malignant epithelial ovarian tumors
verfasst von: Sherif B. Elsherif
Priya R. Bhosale
Chandana Lall
Christine O. Menias
Malak Itani
Kristina A. Butler
Dhakshinamoorthy Ganeshan
Publikationsdatum: 05.06.2021
Verlag: Springer US
Erschienen in: Abdominal Radiology / Ausgabe 6/2021
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-021-03081-0

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Current update on malignant epithelial ovarian tumors

Abstract

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Visual abstract for Abdominal Radiology: what it is, why we need it and how to make it

Real-time virtual sonography-assisted radiofrequency ablation in liver tumors with conspicuous or inconspicuous images or peritumoral landmarks under ultrasonography

Decoding incidental ovarian lesions: use of texture analysis and machine learning for characterization and detection of malignancy

The utility of an under-distended gallbladder on ultrasound in ruling out acute cholecystitis

A radiomic nomogram based on arterial phase of CT for differential diagnosis of ovarian cancer

Placental thickness correlates with placenta accreta spectrum (PAS) disorder in women with placenta previa

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie